Strides Arcolab Ltd (Strides) profits rose 12.97 per cent to Rs 52.49 crore on a consolidated basis for the third quarter (Q3) of this fiscal.
The company’s revenues fell 23 per cent to Rs 596.19 crore in the same quarter, while EPS stood at Rs 8.94 compared with Rs 7.99.
Revenues fell due to divestment of Ascent Australasian business.
“Our performance this quarter reflects the momentum we have carried through the year in both Agila and pharma divisions. Both divisions continue to deliver on all key operating indicators including regulatory filings, approvals and product launches. We are particularly pleased with our operating leverage that has been consistently achieved,” said Arun Kumar, Vice-Chairman and Group CEO, Strides Arcolab.